However, subsequent studies confirm that the silencing of TRIM22 decreases chronic myeloid leukemia K562 cell proliferation and invasion and triggers cell cycle arrest and apoptosis, indicating an oncogenic role of TRIM22 [21]. Here, TRIM22 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.